Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Global Blood Therapeutics, Inc is a biotechnology business based in the US. Global Blood Therapeutics shares (GBT) are listed on the NASDAQ and all prices are listed in US Dollars. Global Blood Therapeutics employs 352 staff and has a trailing 12-month revenue of around USD$47.7 million.
Since the stock market crash in March caused by coronavirus, Global Blood Therapeutics's share price has had significant negative movement.
Its last market close was USD$42.61, which is 41.38% down on its pre-crash value of USD$72.69 and 6.66% up on the lowest point reached during the March crash when the shares fell as low as USD$39.95.
If you had bought USD$1,000 worth of Global Blood Therapeutics shares at the start of February 2020, those shares would have been worth USD$683.40 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$647.25.
|Latest market close||USD$42.61|
|52-week range||USD$39.95 - USD$87.54|
|50-day moving average||USD$57.9297|
|200-day moving average||USD$65.8158|
|Wall St. target price||USD$109.74|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.645|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||-0.44%|
|1 month (2020-10-23)||-24.40%|
|3 months (2020-08-24)||-31.94%|
|6 months (2020-05-22)||-38.62%|
|1 year (2019-11-22)||-24.10%|
|2 years (2018-11-23)||23.36%|
|3 years (2017-11-24)||8.70%|
|5 years (2015-11-24)||-12.51%|
|Revenue TTM||USD$47.7 million|
|Gross profit TTM||USD$2.1 million|
|Return on assets TTM||-25.31%|
|Return on equity TTM||-47.73%|
|Market capitalisation||USD$3.8 billion|
TTM: trailing 12 months
There are currently 9.3 million Global Blood Therapeutics shares held short by investors – that's known as Global Blood Therapeutics's "short interest". This figure is 3.2% up from 9.0 million last month.
There are a few different ways that this level of interest in shorting Global Blood Therapeutics shares can be evaluated.
Global Blood Therapeutics's "short interest ratio" (SIR) is the quantity of Global Blood Therapeutics shares currently shorted divided by the average quantity of Global Blood Therapeutics shares traded daily (recently around 876013.70510397). Global Blood Therapeutics's SIR currently stands at 10.58. In other words for every 100,000 Global Blood Therapeutics shares traded daily on the market, roughly 10580 shares are currently held short.
However Global Blood Therapeutics's short interest can also be evaluated against the total number of Global Blood Therapeutics shares, or, against the total number of tradable Global Blood Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Global Blood Therapeutics's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Global Blood Therapeutics shares in existence, roughly 150 shares are currently held short) or 0.1746% of the tradable shares (for every 100,000 tradable Global Blood Therapeutics shares, roughly 175 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Global Blood Therapeutics.
Find out more about how you can short Global Blood Therapeutics stock.
We're not expecting Global Blood Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Global Blood Therapeutics's shares have ranged in value from as little as $39.95 up to $87.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Global Blood Therapeutics's is 1.7358. This would suggest that Global Blood Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Steps to owning and managing CBAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHAP, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRS, with 24-hour and historical pricing before you buy.
Steps to owning and managing AXLA, with 24-hour and historical pricing before you buy.
Steps to owning and managing ALOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMPE, with 24-hour and historical pricing before you buy.
Steps to owning and managing UHAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ALIM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.